Metys Pharmaceuticals
Metys Pharmaceuticals AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, developing MP-101 and related non-opioid programs for the prevention and treatment of chemotherapy-induced peripheral neuropathy and broader neuropathic pain conditions. It operates as a wholly-owned subsidiary of Novaremed AG following a 2021 acquisition.
- Company typePrivate
- Founded2013
- HeadquartersBasel, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Metys Pharmaceuticals does
Metys Pharmaceuticals AG is a clinical-stage biopharmaceutical company headquartered in Basel, Switzerland, developing non-opioid therapeutics for chronic and neuropathic pain. Its lead program, MP-101, is being investigated for the prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN), a condition with limited non-opioid treatment options. The company's pipeline spans both clinical and preclinical development projects targeting a broader spectrum of neuropathic pain indications, with an emphasis on non-opioid mechanisms that avoid the dependency and addiction risks associated with opioid analgesics.
On September 7, 2021, Metys was acquired by Novaremed AG, a privately held clinical-stage biopharmaceutical company, in an all-share transaction. Metys now operates as a wholly-owned subsidiary of Novaremed, with its development programs integrated into Novaremed's broader chronic pain pipeline. The subsidiary model allows Metys' programs to access Novaremed's development resources while retaining their distinct non-opioid positioning.
The company is small — 1–10 employees — with leadership structured around consulting engagements. Founder and CEO Michael Scherz is supported by a consulting Chief Medical Officer, Head of Clinical Operations, Head of Chemistry, and Head of Preclinical Development. To date, Metys has secured approximately $1.5M in cumulative funding, including a 2019 non-dilutive grant from EISMEA. The company has no marketed products, no disclosed revenue, and no commercial sales infrastructure, consistent with a pre-clinical/early-clinical asset strategy.
Metys Pharmaceuticals firmographics
Firmographics- Name
- Metys Pharmaceuticals
- Legal name
- Metys Pharmaceuticals AG
- Website
- https://metys-pharma.ch
- Company type
- Private
- Founded year
- 2013
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- Metys Pharmaceuticals AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, developing MP-101 and related non-opioid programs for the prevention and treatment of chemotherapy-induced peripheral neuropathy and broader neuropathic pain conditions. It operates as a wholly-owned subsidiary of Novaremed AG following a 2021 acquisition.
- Ownership category
- akta.pro rank
Where Metys Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Metys Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Metys Pharmaceuticals product offering
Product offeringCore offering
Metys Pharmaceuticals is a clinical-stage biopharmaceutical company developing MP-101, a non-opioid therapeutic candidate for the prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN) and broader neuropathic pain indications. The company conducts clinical and preclinical development of small-molecule pain therapies that target a wider spectrum of neuropathic pain conditions, including potential prevention applications. As of September 7, 2021, Metys operates as a wholly-owned subsidiary of Novaremed AG.
Product overview
Metys Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing non-opioid treatments for chronic and neuropathic pain. The company had clinical and preclinical development programs for innovative pain treatment approaches. As of September 7, 2021, Metys Pharmaceuticals AG became a wholly-owned subsidiary of Novaremed AG through an all-share acquisition, which broadened Novaremed's pipeline to include both clinical and preclinical development projects targeting neuropathic pain indications and broader pain management applications including prevention.
Differentiator
Problem solved
Functional benefit
Products and services
- MP-101
Companies that use Metys Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
Metys Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Metys Pharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Novaremed AGcoreNovaremed AG, a privately held clinical-stage biopharmaceutical company, acquired Metys Pharmaceuticals AG including all of its development programs in an all-share transaction. This acquisition broadens Novaremed's existing pipeline by adding both clinical and preclinical development projects based on an innovative approach for non-opioid chronic pain treatment. Metys Pharmaceuticals AG operates as a wholly-owned subsidiary of Novaremed AG.
Recent moves4 records
Expansion highlights4 records
Metys Pharmaceuticals competitors and assessment
Company assessmentPeers
Emerging players
- Regenacy Pharmaceuticals: US clinical-stage company developing ricolinostat and other HDAC6 inhibitors for chemotherapy-induced peripheral neuropathy and diabetic neuropathy. Closest direct peer to Metys because of an explicit CIPN focus and similar clinical-stage positioning.
- Aptinyx Inc. Clinical-stage biopharma developing NMDA receptor modulators for chronic pain and CNS indications. Comparable to Metys as a small, non-opioid pain-focused developer advancing novel CNS-mechanism candidates through mid-stage clinical trials.
- Algiax Pharmaceuticals: European clinical-stage company developing lead candidate AP-325 for neuropathic pain, including chemotherapy-induced peripheral neuropathy. Directly comparable to Metys on indication (CIPN), stage, and European operational footprint.
Broad incumbents
- Vertex Pharmaceuticals: Large commercial-stage biopharma with a growing non-opioid pain franchise (Journavx/suzetrigine for acute pain and expanding into neuropathic pain). Comparable to Metys as a serious non-opioid pain innovator, but with vastly greater resources and a commercial-stage infrastructure Metys lacks.
Direct peers
- Novaremed AG: Swiss clinical-stage biopharma developing non-opioid treatments for chronic neuropathic pain (notably diabetic peripheral neuropathy with lead candidate NRD.E1). Direct parent of Metys Pharmaceuticals and the most directly comparable peer given shared mechanism focus, geography (Basel), and non-opioid chronic pain strategy.
Regional players
- Asahi Kasei Pharma: Japanese specialty pharma with development activity in neuropathy and pain indications, including programs targeting diabetic and chemotherapy-induced neuropathy. Comparable in therapeutic focus on neuropathy, though regional (Japan-anchored) and at a larger corporate scale.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Metys Pharmaceuticals social profiles
Digital presenceMetys Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Metys Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles5 records
Metys Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Metys Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Metys Pharmaceuticals
What does Metys Pharmaceuticals do?
Metys Pharmaceuticals is a clinical-stage biopharmaceutical company developing MP-101, a non-opioid therapeutic candidate for the prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN) and broader neuropathic pain indications. The company conducts clinical and preclinical development of small-molecule pain therapies that target a wider spectrum of neuropathic pain conditions, including potential prevention applications. As of September 7, 2021, Metys operates as a wholly-owned subsidiary of Novaremed AG.
Is Metys Pharmaceuticals a public or private company?
Metys Pharmaceuticals is a private company. It is classified as corporate owned and is currently acquired.
When was Metys Pharmaceuticals founded?
Metys Pharmaceuticals was founded in 2013. It employs 1 to 10 people.
Where is Metys Pharmaceuticals based?
Metys Pharmaceuticals is headquartered in Basel, Switzerland, in the Europe region.
Who are Metys Pharmaceuticals's main competitors?
Eli Lilly and Company is listed as a peer. Emerging players are Regenacy Pharmaceuticals, Aptinyx Inc. and Algiax Pharmaceuticals. Vertex Pharmaceuticals is listed as a broad incumbent. Novaremed AG is listed as a direct peer. Asahi Kasei Pharma is listed as a regional player.
Does Metys Pharmaceuticals have an API?
No public API is recorded for Metys Pharmaceuticals.